Recombinant Cynomolgus CD79B protein, His-Avi-tagged, Biotinylated

• Cat.No.: CD79B-2990C
• Product Overview: Biotinylated Recombinant Cynomolgus CD79B protein(Ala 30-Asp 161), fused with His and Avi tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Cynomolgus
• Tag: His&Avi
• Form: Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4. Normally trehalose is added as protectant before lyophilization.
• Molecular Mass: This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).The protein has a calculated MW of 18.9 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Protein length: Ala 30-Asp 161
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >90% as determined by SDS-PAGE.
• Storage: For long term storage, the product should be stored at lyophilized state at-20°C or lower.Please avoid repeated freeze-thaw cycles. This product is stable after storage at:-20°C to-70°C for 12 months in lyophilized state;-70°C for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Reviews

04/26/2023

Renowned for its reliability and consistency, this protein offers researchers the confidence to achieve accurate and reproducible results in their studies.

11/16/2021

The CD79B protein comes highly recommended for its outstanding performance in ELISA assays.

10/26/2018

One notable advantage of the CD79B protein is the excellent technical support provided by its manufacturer.

Q&As

How does CD79B-targeted immunotherapy differ from traditional chemotherapy in treating B cell malignancies?

CD79B-targeted immunotherapy aims to specifically target B cells, potentially reducing side effects compared to non-specific chemotherapy.

How does CD79B contribute to the development of personalized treatment strategies for B cell diseases?

Analyzing CD79B expression helps tailor treatment plans, allowing for more personalized and effective approaches.

Can CD79B be used as a biomarker for minimal residual disease in B cell malignancies?

Yes, monitoring CD79B levels can aid in detecting minimal residual disease, providing insights into treatment response.

Are there any challenges or limitations associated with relying on CD79B as a diagnostic marker?

Variability in CD79B expression among different B cell disorders may pose challenges in its use as a standalone diagnostic marker.

Are there any clinical trials investigating the therapeutic potential of CD79B-targeted drugs?

Yes, several clinical trials are exploring the efficacy of CD79B-targeted drugs in various B cell disorders.